John W. Belmont, MD, PhD, FAAP, FACMG
Causal reasoning applied to genomics, genetic testing, and precision medicine.
What I Do
My work sits at the intersection of genomic epidemiology, causal inference, and the evidence questions that matter for clinical and commercial decisions. I focus on problems that require deep methodological judgment — study design for genetic biomarker validation, causal analysis of molecular diagnosis, clinical utility measurement, health economics modeling for genomic tests, and statistical analysis of rare and common variant data at scale.
I work selectively with pharma and diagnostics companies on specific, scoped engagements where the question is genuinely hard. I also collaborate with academic physician-scientists on problems in human genetics and precision medicine.
Clinical Utility Evidence
Designing and analyzing studies that demonstrate — causally, not just associatively — that a genetic test improves patient outcomes. Most published evidence doesn’t clear this bar. I know how to build the case that does.
Genomic Study Design & Analysis
Rare variant association studies, composite polygenic score development and validation, counterfactual modeling of diagnostic certainty, and large-scale biobank analysis. Active work in UK Biobank and collaborative work in All of Us. Methods grounded in causal inference rather than descriptive association.
Strategic Translation
Helping technically sophisticated teams understand what their data actually shows — and what it will take to convince a payer, a guideline committee, or a clinical audience. Evidence strategy for Market Access and Medical Affairs.
Why Should We Do Genetic Testing?
If a doctor orders a genetic test, will it have Clinical Utility? It’s a surprisingly difficult question to answer. Will patient outcomes be improved because the test allowed the doctor to make a better diagnosis? The diagram (as a directed acyclic graph — DAG — that lends itself to causal modeling) shows an ideal process in which getting a genetic test gives a clinically useful result that improves management and outcome. In the blog below I discuss how one can measure clinical utility. It’s of great practical importance that doctors select patients with signs and symptoms suggestive of genetic disease for genetic testing. The entire path has to be understood through the lens of that selection.
Profile
I’m a physician-scientist who has spent forty years at the intersection of human genetics, clinical medicine, and translational research — at Baylor College of Medicine, Texas Children’s Hospital, and Illumina. My current focus is causal inference applied to genomics: how we move from genetic association to evidence that actually changes clinical decisions.
I consult selectively on problems where that distinction matters.
Training & Boards
MD, PhD — Baylor College of Medicine, 1981
Pediatrics — American Board of Pediatrics
Medical Genetics — American Board of Medical Genetics
Academic
Professor (tenured), Molecular & Human Genetics and Pediatrics, BCM
Assistant Investigator, Howard Hughes Medical Institute (1987–1993)
PI on NIH and foundation grants for 28 years
Chair, NIH Center for Inherited Disease Research (2024–2025)
Industry & Entrepreneurship
Senior Principal Medical Scientist, Illumina Medical Genomics Research
Co-founder & VP, Seqwright, Inc. (with Richard Gibbs, 1994–2012)
Output
250+ peer-reviewed publications · >45,000 citations
Clinical practice: 28 years in Pediatrics and Medical Genetics at Texas Children’s Hospital. Co-founder, Cardiovascular Genetics Clinic (1997). Co-founder and Associate Director, Cardiovascular Research Institute, BCM. Chair, Economics of Genetics Services Committee, American College of Medical Genetics (2023–2025). Member: ASHG, ACMG, Society for Pediatric Research, ASCI, Association of American Physicians.
Selected Recent Publications
1. The Causal Pivot: A structural approach to genetic heterogeneity and variant discovery in complex diseases. Shaw CA, Williams CJ, Tan T, Illera D, Di N, Shulman J, Belmont JW. Am J Hum Genet. 2025. doi:10.1016/j.ajhg.2025.07.012
2. A meta-analysis of diagnostic yield and clinical utility of genome and exome sequencing in pediatric rare and undiagnosed genetic diseases. Pandey R, …Belmont J, Veenstra DL, Peng S. Genet Med. 2025. PMID: 40022598
3. The impact of clinical genome sequencing in a global population with suspected rare genetic disease. Thorpe E, …Belmont J, Taft RJ. Am J Hum Genet. 2024;111(7):1271-1281. PMID: 38843839
4. Development of a comprehensive cardiovascular disease genetic risk assessment test. Amendola LM, …Belmont J, Lanfear DE, Taft RJ. medRxiv. 2024. PMID: 38766118
5. Evidence review and considerations for use of first line genome sequencing to diagnose rare genetic disorders. Wigby KM, …Belmont J, …Taft RJ. NPJ Genom Med. 2024;9(1):15. PMID: 38409289
6. The Expansion of Genetic Testing in Cardiovascular Medicine: Preparing the Cardiology Community for the Changing Landscape. Reza N, Alford RL, Belmont JW, Marston N. Curr Cardiol Rep. 2024;26(3):135-146. PMID: 38277082
7. Genetic Epidemiology Highlights the Role of Aortic Strain and Distensibility in Cardiovascular Disease. Belmont JW. J Am Coll Cardiol. 2023;81(14):1336-1338. PMID: 37019579
8. Considering the Genetic Architecture of Hypoplastic Left Heart Syndrome. Belmont JW. J Cardiovasc Dev Dis. 2022;9(10):315. PMID: 36286267
9. Recommendations for whole genome sequencing in diagnostics for rare diseases. Souche E, …Belmont JW, …Weiss MM. Eur J Hum Genet. 2022;30(9):1017-1021. PMID: 35577938
10. Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases. Incerti D, …Belmont JW, Schroeder BE. Genet Med. 2021. PMID: 34906478
11. Effect of Whole-Genome Sequencing on the Clinical Management of Acutely Ill Infants With Suspected Genetic Disease: A Randomized Clinical Trial. Krantz ID, …JAMA Pediatr. 2021. PMID: 34570182
12. The diagnostic trajectory of infants and children with clinical features of genetic disease. Schroeder BE, …Belmont JW. NPJ Genom Med. 2021;6:98. PMID: 34811359
13. Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. Bick D, Jones M, Taylor SL, Taft RJ, Belmont J. J Med Genet. 2019;56(12):783-791. PMID: 31023718
14. A Diagnosis for All Rare Genetic Diseases: The Horizon and the Next Frontiers. Boycott KM, …Belmont J, …Baynam G. Cell. 2019;177(1):32-37. PMID: 30901545
Recent Writing
What is the Clinical Utility of a Genetic Test?
belmontgenetics.org 